Literature DB >> 10851386

Status epilepticus with neuron-reactive serum antibodies: response to plasma exchange.

M Lousa1, S Sanchez-Alonso, R Rodriguez-Diaz, J Dalmau.   

Abstract

The authors report a patient with partial and secondarily generalized status epilepticus who required 70 days of general anesthesia for seizure control. Although antiepileptic medications failed to control the seizures, they resolved with plasma exchange. The patient's serum reacted with rat cerebral cortex, hippocampus, and cerebellum, but not with cells expressing the glutamate receptor GluR3. These findings suggest an immune response against neuronal antigens other than GluR3.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10851386     DOI: 10.1212/wnl.54.11.2163

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Status Epilepticus.

Authors:  Elizabeth J. Waterhouse
Journal:  Curr Treat Options Neurol       Date:  2002-07       Impact factor: 3.598

Review 2.  Eponym : Rasmussen syndrome.

Authors:  Mario Mastrangelo; Rosanna Mariani; Alessandra Menichella
Journal:  Eur J Pediatr       Date:  2010-02-23       Impact factor: 3.183

Review 3.  Immunomodulatory therapies in neurologic critical care.

Authors:  Logan M McDaneld; Jeremy D Fields; Dennis N Bourdette; Anish Bhardwaj
Journal:  Neurocrit Care       Date:  2009-09-23       Impact factor: 3.210

4.  Status epilepticus: current treatment strategies.

Authors:  Edward M Manno
Journal:  Neurohospitalist       Date:  2011-01

5.  A spicy status: Synthetic cannabinoid (spice) use and new-onset refractory status epilepticus-A case report and review of the literature.

Authors:  Marc-Alain Babi; Christopher P Robinson; Carolina B Maciel
Journal:  SAGE Open Med Case Rep       Date:  2017-12-05

Review 6.  Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review.

Authors:  Laurent M Willems; Sebastian Bauer; Kolja Jahnke; Martin Voss; Felix Rosenow; Adam Strzelczyk
Journal:  CNS Drugs       Date:  2020-08       Impact factor: 5.749

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.